These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26911854)

  • 1. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.
    Gomez IG; Nakagawa N; Duffield JS
    Am J Physiol Renal Physiol; 2016 May; 310(10):F931-44. PubMed ID: 26911854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic microRNAs in polycystic kidney disease.
    Yheskel M; Patel V
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):282-289. PubMed ID: 28399020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.
    Peters LJF; Floege J; Biessen EAL; Jankowski J; van der Vorst EPC
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
    Ghosh N; Katare R
    Cardiovasc Diabetol; 2018 Mar; 17(1):43. PubMed ID: 29566757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs and their role in progressive kidney diseases.
    Kato M; Arce L; Natarajan R
    Clin J Am Soc Nephrol; 2009 Jul; 4(7):1255-66. PubMed ID: 19581401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
    Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
    Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis.
    Price NL; Miguel V; Ding W; Singh AK; Malik S; Rotllan N; Moshnikova A; Toczek J; Zeiss C; Sadeghi MM; Arias N; Baldán Á; Andreev OA; Rodríguez-Puyol D; Bahal R; Reshetnyak YK; Suárez Y; Fernández-Hernando C; Lamas S
    JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31613798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?
    Biglino G; Caputo M; Rajakaruna C; Angelini G; van Rooij E; Emanueli C
    Pharmacol Ther; 2017 Feb; 170():192-204. PubMed ID: 27902930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered microRNA therapeutics.
    Gibson NW
    J R Coll Physicians Edinb; 2014; 44(3):196-200. PubMed ID: 25318394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs in the skin: role in development, homoeostasis and regeneration.
    Horsburgh S; Fullard N; Roger M; Degnan A; Todryk S; Przyborski S; O'Reilly S
    Clin Sci (Lond); 2017 Aug; 131(15):1923-1940. PubMed ID: 28705953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as mediators and therapeutic targets in chronic kidney disease.
    Lorenzen JM; Haller H; Thum T
    Nat Rev Nephrol; 2011 May; 7(5):286-94. PubMed ID: 21423249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-27a ameliorates inflammatory damage to the blood-spinal cord barrier after spinal cord ischemia: reperfusion injury in rats by downregulating TICAM-2 of the TLR4 signaling pathway.
    Li XQ; Lv HW; Wang ZL; Tan WF; Fang B; Ma H
    J Neuroinflammation; 2015 Feb; 12():25. PubMed ID: 25876455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs in health and disease--basic science and clinical applications.
    Osman A
    Clin Lab; 2012; 58(5-6):393-402. PubMed ID: 22783567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling.
    Teoh JP; Bayoumi AS; Aonuma T; Xu Y; Johnson JA; Su H; Weintraub NL; Tang Y; Kim IM
    J Mol Cell Cardiol; 2018 May; 118():225-236. PubMed ID: 29627294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs in cardiovascular disease.
    Gurha P
    Curr Opin Cardiol; 2016 May; 31(3):249-54. PubMed ID: 26885771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.
    Raue R; Frank AC; Syed SN; Brüne B
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction.
    Schauerte C; Hübner A; Rong S; Wang S; Shushakova N; Mengel M; Dettling A; Bang C; Scherf K; Koelling M; Melk A; Haller H; Thum T; Lorenzen JM
    Kidney Int; 2017 Sep; 92(3):646-656. PubMed ID: 28396121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs and gene regulation in breast cancer.
    Abdalla F; Singh B; Bhat HK
    J Biochem Mol Toxicol; 2020 Nov; 34(11):e22567. PubMed ID: 32729651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA profiling of urinary exosomes to assess the progression of acute kidney injury.
    Sonoda H; Lee BR; Park KH; Nihalani D; Yoon JH; Ikeda M; Kwon SH
    Sci Rep; 2019 Mar; 9(1):4692. PubMed ID: 30886169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.